Human IL-29 (IFN-λ1) Antibody

Mouse IgG1 (clone 6A11) - Recombinant

ABOUT

Recombinant anti-human IL-29 neutralizing monoclonal antibody

Anti-hIL-29-mIgG1 is a monoclonal antibody (mAb) targeting human interleukin 29 (hIL-29).

It was previously extracted from hybridoma cells (clone 6A11). It is now expressed and produced in Chinese hamster ovary (CHO) cells, ensuring reliability and lot-to-lot reproducibility. This antibody has been selected for its ability to efficiently neutralize the biological activity of hIL-29. Since mice lack an active IL-29 gene, there is no cross-reactivity.

IL-29 (also known as interferon lambda 1) is a member of the type III interferon (IFN lambda) cytokine family that exhibits several common features with type I IFNs: antiviral activity and antitumor activity [1, 2].

More details More details

This antibody can be used together with HEK-Blue™ IFN-λ Cells treated with recombinant human IL-29 for screening and neutralization assays to block type III interferon signaling.

 

Key features

  • Each lot is functionally tested and validated.
  • The complete sequence of the antibody construct has been verified.
  • The absence of endotoxins is determined by the EndotoxDetect™ assay.

     

The hybridoma-derived Anti-hIL-29-IgG (mabg-hil29-3) antibody has been replaced by Anti-hIL-29-mIgG1 (mab9-hil29), which is produced by recombinant technology and purified from CHO cells.

 

1. Donnelly RP. & Kotenko SV., 2010. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res. 30(8):555-64.
2. Li M. et al., 2009. Interferon-ls: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol., 86:23-32.

All products are for research use only, and not for human or veterinary use.

SPECIFICATIONS

Specifications

Target

IL-29, IFNλ1, IFNL1

Target species

Human

Applications

Neutralization (tested)

ELISA

Species
Mouse
Isotype
mIgG1
kappa
Clone
6A11
Tag
Tag-free
Source
CHO
Production details
Animal-free
Purification
Affinity chromatography
Formulation buffer

Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative
Azide-free
Purity
≥95% (SDS-PAGE)
Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Endotoxin

Negative (tested using EndotoxDetect™ assay)

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hIL-29-mIgG1
  • Cat code: 
    mab9-hil29
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Interleukin-29 (IL-29) is a member of the type III interferon (IFN lambda) cytokine family, which comprises four distinct proteins called IFN-λ1 (interleukin-29, IL-29), IFN-λ2 (IL-28A), IFN-λ3 (IL-28B), and the poorly secreted IFN-λ4. It should be noted that in the mouse genome, IL-29 is a pseudogene. Type III IFNs exhibit several common features with type I IFNs: antiviral activity and antitumor activity [1, 2]. In fact, it has been demonstrated that IL-29 works together with type I IFN to promote an antiviral response to hepatitis [3]. IL-29 is produced by monocytes and dendritic cells in response to viral infection and stimulation with toll-like receptor (TLR) ligands [4]. IL-29 exerts its action following binding to a heterodimeric protein complex composed of two subunits, IFN lambda receptor 1 (IFNLR1) and IL-10 receptor beta (IL10Rβ). This leads to the recruitment of the Janus kinases, JAK1 and TyK2, and phosphorylation of STAT1 and STAT2, which then dimerize and interact with IFN regulatory factor 9 (IRF9), forming the ISGF3 complex. ISGF3 binds to IFN-stimulated response elements (ISRE) in the promoters of IFN-stimulated genes (ISG) to regulate their expression.

Besides its antiviral function, IFN-λ signaling also plays an important role in non-infectious diseases like autoimmune diseases and cancer [5-6]. Increased levels of IL‐29 were detected in the serum of patients with rheumatoid arthritis, psoriasis, as well as systemic sclerosis [6]. On the other hand, IFN-λ demonstrates broad-spectrum inhibitory activity across cancers, including bladder cancer, melanoma, colorectal carcinoma, and HPV-associated cervical malignancies [6]. Further research is required to elucidate the dual role of IFN-λ and to gain a deeper understanding of its complex role in immune regulation.

 

1. Donnelly RP. & Kotenko SV., 2010. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res. 30(8):555-64.
2. Li M. et al., 2009. Interferon-ls: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol., 86:23-32.
3. Pagliaccetti NE. et al., 2008. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem. 283(44):30079-89.
4. Wolk K. et al., 2008. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J. Leukoc Biol. 83(5):1181-93.
5. Wang JM, et al., 2019. Insights into IL-29: Emerging role in inflammatory autoimmune diseases. J Cell Mol Med. 23(12):7926-7932
6. Tang B, et al., 2025. IFN-λ: Unleashing Its Potential in Disease Therapies From Acute Inflammation Regulation to Cancer Immunotherapy. Immunology. 176(2):197-214. 

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?